High Availability of the α7-Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using 18F-ASEM PET Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Emerging evidence supports a hypothesized role for the α7-nicotinic acetylcholine receptor (α7-nAChR) in the pathophysiology of Alzheimer's disease. 18F-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-18F-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of α7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed 18F-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher 18F-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of α7-nAChR in MCI. 18F-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of 18F-ASEM PET to examine further the relationship between α7-nAChR availability and MCI.


  • Coughlin, Jennifer M
  • Rubin, Leah H
  • Du, Yong
  • Rowe, Steven P
  • Crawford, Jeffrey L
  • Rosenthal, Hailey B
  • Frey, Sarah M
  • Marshall, Erica S
  • Shinehouse, Laura K
  • Chen, Allen
  • Speck, Caroline L
  • Wang, Yuchuan
  • Lesniak, Wojciech G
  • Minn, Il
  • Bakker, Arnold
  • Kamath, Vidyulata
  • Smith, Gwenn S
  • Albert, Marilyn S
  • Azad, Babak Behnam
  • Dannals, Robert F
  • Horti, Andrew
  • Wong, Dean F
  • Pomper, Martin G

publication date

  • March 2020